Cancers, Free Full-Text

Overexpression of Exportin-1 (XPO1), a key regulator of nuclear-to-cytoplasmic transport, is associated with inferior patient outcomes across a range of adult malignancies. Targeting XPO1 with selinexor has demonstrated promising results in clinical trials, leading to FDA approval of its use for multiple relapsed/refractory cancers. However, XPO1 biology and selinexor sensitivity in childhood cancer is only recently being explored. In this review, we will focus on the differential biology of childhood and adult cancers as it relates to XPO1 and key cargo proteins. We will further explore the current state of pre-clinical and clinical development of XPO1 inhibitors in childhood cancers. Finally, we will outline potentially promising future therapeutic strategies for, as well as potential challenges to, integrating XPO1 inhibition to improve outcomes for children with cancer.

Frontiers Cell-Free DNA: Hope and Potential Application in Cancer

Cancers, Free Full-Text

Game Rong Den 5 Get File - Colaboratory

Cancer Innovation - Wiley Online Library

Cancer treatment and survivorship statistics, 2022 - Miller - 2022

Profiling molecular regulators of recurrence in chemorefractory

Classification of biliary tract cancers established by JSHBPS: 3rd

What is cancer of unknown primary (CUP)?

Multimodal analysis of methylomics and fragmentomics in plasma

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

𝓙𝓾𝓵𝓲𝓪𝓷𝓮_𝓛𝓲𝓫𝓮𝓻𝓽𝓸 (@JulianeLiberto) / X